Equibles does not estimate personal net worth.
Get an email with a short summary when GeneDx Holdings Corp. publishes a filing, an earnings call transcript or a press release.
Get WGS alertsKevin Feeley is recorded as CFO at GeneDx Holdings Corp. (WGS). The newest filing on record that lists Kevin Feeley as CFO at GeneDx Holdings Corp. (WGS) is dated April 30, 2026. GeneDx Holdings Corp. reported in an 8-K filed August 26, 2022 that Kevin Feeley was appointed Chief Financial Officer, effective August 25, 2022. The proxy statement of GeneDx Holdings Corp. reports total compensation of $4,688,926 for Kevin Feeley in fiscal 2025, including a base salary of $500,600. Disclosed compensation is on record for 4 fiscal years. Kevin Feeley has spoken on 17 earnings calls and 4 other investor events across 1 company, most recently for GeneDx Holdings Corp. on September 8, 2026. GeneDx Holdings Corp. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at GeneDx Holdings Corp. includes Eric Schadt (CEO and Board Member), Katherine Stueland (CEO and Board Member), Richard Miao (CFO) and 7 others.
“On August 25, 2022, Kevin Feeley, the Company's current Senior Vice President of Operations and Head of GeneDx, was appointed to also serve as the Chief Financial Officer, effective August 25, 2022.”
“Main operating lab down in Gaithersburg spun out of the NIH two scientists who wanted to focus on rare disease diagnosis, and that's what GNDX does best.”
“And we're pleased, in particular, with the highlight of continuing to demonstrate really strong demand for our services, which are anchored on providing exome and whole genome sequencing for pediatric rare disease volume growth, 32%. for the year.”
“Thanks, Mark, and good afternoon, everyone. total revenues were $114.4 million, up 11% year-over-year. Exome and genome revenues were $100.3 million, up 17%, with exome and genome result volume of 30,785 tests, up 32%.”
“Yeah, look, I think it really starts with the problem we're trying to solve nearly 1 in 10 Americans has an undiagnosed rare disease it's a much larger patient population than I think the name rare disease gives rise to and if you look at where those patients have been diagnosed in the past it's primarily been expert…”
“In the first quarter, we delivered $102.3 million of total revenue, including $90.6 million of exome and genome revenue, up 27%, and test result volume of 27,488 tests, up 34%.”
Start not stated–present
Last confirmed April 30, 2026
Diagnostics & Research · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | GeneDx Holdings Corp. (WGS) | Chief Financial Officer | $500,600 | $4,688,926 |
| 2024 | GeneDx Holdings Corp. (WGS) | CFO | $450,000 | $1,349,600 |
| 2023 | GeneDx Holdings Corp. (WGS) | CFO | $450,000 | $1,552,535 |
| 2022 | GeneDx Holdings Corp. (WGS) | Chief Financial Officer | $294,231 | $3,657,680 |
